The transaction adds FV-100, an orally bioavailable bicyclic nucleoside analogue for the treatment of shingles and a series of preclinical compounds for the treatment of human cytomegalovirus disease to the Inhibitex pipeline.
Russell Plumb, president and CEO of Inhibitex, said: “The closing of this transaction represents another significant step forward in our effort to build a diverse pipeline of high-value, differentiated anti-infectives, each of which has the potential to improve upon the standard of care.”